Amare NeuCollagen™ Ingredient Nutritional Clinical Studies Overview

Table Contents

1. Amare NeuCollagen™ Overview
2. Amare NeuCollagen Key Ingredients & Benefits
3. Key Ingredient Clinical Studies Highlights

a. Collavant® n2 Clinical Studies (2)

b. Mobilee® Clinical Studies (4)

c. GPX-4™ Clinical Studies (3)

d. Dermial® Clinical Studies (2)

e. Cerebiome® Clinical Studies (5)

Note: this is a high-level representation showcasing 16 of the 25 total Ingredient Nutritional Clinical Studies for the ingredients the formula.

What is Amare NeuCollagen™?

Amare NeuCollagen™ is a revolutionary collagen formula that merges smarter science with bio-intelligence to support joint mobility, youthful skin & cognitive health.*  

While typical collagen supplements make you choose between feeling, looking and living younger,  Amare NeuCollagen is the best collagen supplement for those that simply want it all (in one).* 

Amare NeuCollagen provides 6 whole body wellness benefits with power-packed ingredients backed by a combined 25 nutritional clinical studies.

1. Inhibit Collagen Loss* 
   Collavant® n2 works through the gut-immune connection to slow the breakdown of collagen promoting joint lubrication, mobility and comfort while also supporting quicker recovery.* 
   -- Collavant® n2 was shown to provide a 44% reduction in joint discomfort. 
2. Maintain Joint Comfort and Mobility*  
   Mobilee® Hyaluronic Acid Matrix clinically shown to lower Prostaglandin E2, a compound linked to joint discomfort, helping support joint comfort and overall joint function.* 
   -- Mobilee® was shown to boost hyaluronic acid more than 200x compared to the baseline.
3. Muscle Health* 
   Mobilee® boosts the body’s natural production of hyaluronic acid to support muscle strength and flexibility, while also increasing muscle cell proliferation.* 
   --Mobilee® was shown to improve muscle strength by 17% and improve muscle function by 23%.
4. Boost Natural Collagen Production*
   GPX-4™ is a collagen tripeptide that boosts natural collagen production and helps improve skin elasticity, firmness, and barrier function.* 
   -- GPX-4™ was shown to improve crows feet wrinkles by 937%, improve dermal density by 266% and improve dermal thickness by 548%.
5. Radiate from the Inside Out*
   Dermial® hydrates the skin from within while helping reduce wrinkles and dryness for smoother, more radiant-looking skin.*
   -- Dermial® was shown to reduce wrinkles, increase skin hydration by 13%, and improve skin glow and brightness by 33%.
6. Manage Cortisol & Daily Stress* 
   Cerebiome® is a clinically studied probiotic that supports the gut-brain axis to promote balanced mood, help maintain healthy cortisol levels, and support mental well-being.* 
   --Cerebiome® was shown to reduce feelings of everyday stress by 44%.  

Amare NeuCollagen™ Key Ingredients

Collavant® n2
An undenatured, native type II collagen derived from chicken sternum cartilage. Collavant® n2 has a unique, immune mediated mechanism of action that works through the gut-immune connection to inhibit collagen loss by slowing the breakdown of collagen.* In a nutritional clinical study Collavant® n2 was shown to provide a 44% reduction in joint discomfort. The proprietary combination of Collavant® n2 and Mobilee® is an industry-exclusive blend found only at Amare.

Mobilee® 
A patented, hyaluronic acid matrix with naturally-occurring components including a high concentration of hyaluronic acid, collagen and polysaccharides that promote both joint and muscle health.* In nutritional Clinical Studies Mobilee® was shown to boost hyaluronic acid more than 200x compared to the baseline, improve muscle strength by 17% and improve muscle function by 23%. The proprietary combination of Collavant® n2 and Mobilee® is an industry-exclusive blend found only at Amare.

GPX-4™ 
A low molecular, collagen tripeptide that is quickly absorbed by the body. Once ingested it promotes healthy collagen and hyaluronic acid production helping reduce wrinkles and improve skin elasticity for a healthy, radiant complexion.* In nutritional Clinical Studies GPX-4™ has been shown to improve crows feet wrinkles by 937%, improve dermal density by 266% and improve dermal thickness by 548%. GPX-4™ is an advanced ingredient technology that is industry-exclusive to Amare.

Dermial® 
A hyaluronic acid matrix that promotes the production of hyaluronic acid, type I & III collagen and elastin as well as cell proliferation and migration.* In nutritional Clinical Studies Dermial has been shown to reduce wrinkles, increase skin hydration by 13%, and improve skin glow and brightness by 33%.

Cerebiome® 
Known scientifically as Lactobacillus helveticus R0052, Bifidobacterium longum R0175, and Lacticaseibacillus rhamnosus R0011, helps the body manage everyday stress ​more effectively. Research shows it can reduce feelings ​of everyday stress by 44%. By supporting healthy cortisol levels and key brain chemicals like serotonin, it helps promote a calm mood and overall brain wellness.*

Collavant® n2 Clinical Studies Overview 

EFFICACY AND TOLERABILITY OF NATIVE TYPE-II COLLAGEN FOR JOINT HEALTH IN HEALTHY VOLUNTEERS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

Author(s): Ingrid Möller, Kirsten Martínez, Andrea Terradillos-Guillén, Ester Costa-Larrión, Daniel Martinez-Puig, Javier Velasco-Alvarez 

Abstract

Background: In non-osteoarthritic individuals, the appearance of joint discomfort with physical activity is a potential indicator of initial joint degeneration. Native (undenatured) type-II collagen has been shown to help to maintain joint cartilage and relieve joint  discomfort in patients with OA, through an immune-mediated mechanism of oral tolerance. The present study aimed to evaluate the efficacy and tolerability of native (undenatured) type-II collagen in the joint function of healthy volunteers who experienced joint discomfort due to an extensive exercise protocol. 

Methods: This prospective, randomized double-blind placebo controlled-study included 74 healthy subjects with joint discomfort of 5/10 on a 11-point Likert scale (scale of 0 to 10) within 10 minutes of going up and down stairs and pain score assessed with a Visual Analogue Scale (VAS) during knee movement between 30–50 mm (0-100mm). Participants were randomized 1:1 to receive placebo (PBO) or native type-II collagen (Collavant® n2; CN2) at 40mg/d for 180 days.

All participants provided informed consent before starting the study activities. Joint function was assessed at 60-, 90-, 120- and 180-days, measuring time to experiencing and recovering from knee discomfort after a standardized exercise protocol including going up and down stairs (UDS), standing in one leg (SOL) and cycling in the air (CIA), and the Knee injury and Osteoarthritis Outcome Score (KOOS). An analysis of subjects with discomfort under VAS≤40mm was preplanned (n=22 CN2 and n=21 PBO). The evolution of the participants in relation to the efficacy criteria was evaluated with mixed models using the SAS System® for windows. All statistical tests have been performed at the 5% two-sided level.

Results: The two groups had statistically similar demographics and discomfort at baseline (48 females, 26 males; age 30-65 years). Seventy-four subjects were included (n=35 CN2 group and n=39 PBO group). In the standardized exercise protocol, the time to recover from pain discomfort in the CIA test at day 180 remained constant (0.71min ± 0.10min) for the CN2 group, whereas there was a significant increase compared to baseline in the PBO group (1,17min ±0.09min; p=0.0010). A significant between-group difference (0.46min ± 0.17 min; p=0.0013) was detected for the CIA but not for UDS and SOL. In both groups there was a significant improvement in all KOOS sub-scores at 180 days. Differences from baseline (p < 0.0005) were detected earlier in the CN2 group than in placebo for KOOS knee discomfort (at day 120 vs 180), symptoms (at day 90 vs 120) and Quality of Life (at day 90 vs 180). CN2 subjects with VAS≤40mm had significant improvements (p < 0.005) in all KOOS sub-scores: KOOS pain at day 120, KOOS symptoms at day 60, KOOS Quality of life at day 60, KOOS Sport at day 90 and KOOS ADL at day 180. PBO subjects only had statistically differences versus baseline (p < 0.005) at day 180 in KOOS Symptoms and KOOS Sports. Differences in improvement from baseline between groups were detected at day 180 in KOOS discomfort (CN2 11.1612 ± 2.7689; PBO 2.7778 ± ; 2.6149; p < 0.0292) and KOOS Quality of Life (CN2 14.9346 ± 3.1385; PBO5.6548 ± ; 2.9557; p < 0.0330). Safety outcomes did not differ among the groups, with no adverse events related to the study interventions.

Conclusion: The overall results suggest that the oral supplementation with native (undenatured) type-II collagen to healthy volunteers who experience joint discomfort because of an intensive exercise protocol is safe and well tolerated and could help to improving joint function as well as exercise recovery. The intervention could be beneficial for healthy individuals with an active lifestyle or that practice sports regularly.

Figure 1. Trajectory of the change from baseline in KOOS Pain subscale in the total population (A) and in the subgroup of participants with baseline VAS discomfort during activity ≤40mm. Data points represents means; errors bars, SE; ⁎ p<0.05 vs baseline; # P<0.05 differences vs baseline between groups. 

Effect of Native (undenatured) Type-ii Collagen in CTX-II Biomarker: Results from a Randomized Double-blind Placebo-controlled Study in Healthy Subjects with Joint Discomfort

Author(s): I. Möller, K. Martínez1, A. Terradillos-Guillén2, E. Costa-Larrión2, D. Martínez-Puig2 J. Velasco-Álvarez

Abstract

Background:Type II collagen is the main protein of articular cartilage and is highly specific for this tissue. The urinary concentration of the cross-linked C-terminal telopeptide of type II collagen (CTX-II), reflects collagen destruction, and is considered one of the most validated biomarkers of osteoarthritis. The aim of the present study was to evaluate the effect of supplementation with native type II collagen on the urinary CTX-II concentration in non-osteoarthritis individuals suffering joint discomfort during physical activity.

Methods: Seventy-four healthy subjects with joint discomfort of 5/10 on an 11-point Likert scale within 10 minutes of going up and down stairs and pain score between 30-50mm during knee movement assessed with Visual Analogue Scale (VAS), were randomized to receive native (undenatured) type-II collagen (Collavant n2®; CN2) at 40mg/d or placebo (PBO) for 180 days. Urinary samples were obtained at baseline and at the end of the study. CTX-II concentration was standardized to the total urine creatinine at the time of sampling.

Results: At the end of the study the CTX-II decreased 5.7% in the CN2 group and increased 7.4% in the PBO group as compared to baseline. A significant between-group difference (p=0.0477) was obtained for the subgroup analysis with higher basal pain in movement (VAS>40mm), but not for the general population. In this subgroup CTXII decreased 18.3% in the CN2 group while increased 20.6% in the PBO group.

Conclusion: The supplementation with native (undenatured) type-II collagen could help to protect articular cartilage in healthy volunteers experiencing joint discomfort during physical activity.

Mobilee® Clinical Studies Overview 

Efficacy of oral administration of yoghurt supplemented with a preparation containing hyaluronic acid (MobileeTM) in adults with mild joint discomfort: a randomized,double-blind, placebo-controlled intervention study

Author(s): Daniel Martinez-Puig, Ingrid Möller, César Fernández, Carlos Chetrit

Abstract 

A prospective, randomized, double-blind, placebo-controlled study was designed with 40 healthy individuals with joint discomfort. The effect of oral supplementation with a natural product containing hyaluronic acid included in a yoghurt matrix was evaluated in terms of functional and quality-of-life parameters. An isokinetic dynamometer was used to measure maximum muscle strength, total work and mean power. Participants were divided into 2 groups (n = 20) and ate yoghurt that was either supplemented or not supplemented with the hyaluronic acid product daily for a period of 90 days. The increase in the maximum peak torque of the knee extensors compared to baseline values was 7.6 ± 7.6 Nm for the supplemented yoghurt group and 2.5 ± 4.7 Nm for the control group at 180°/s (P = 0.0582), and 6.5 ± 5.8 Nm for the supplemented yoghurt group and −1.0 ± 7.1 Nm for the control group at 240°/s (P < 0.05). The same pattern of response was observed in total work and in mean power (P < 0.05). Differences were less pronounced in the knee flexors. No differences were detected in the Lequesne score and SF-36 survey except for the social functioning subscale at 1 month follow-up. This prospective placebo-controlled nutritional study confirmed that 3 months of oral administration of a natural product containing HA (Mobilee™) in healthy individuals with joint discomfort of the knee provides improvements in muscle strength.
 

Effectiveness of a low-fat yoghurt supplemented with rooster comb extract on muscle strength in adults with mild knee pain and mechanisms of action on muscle regeneration

Author(s): David Moriña, Sara Fernández-Castillejo, Rosa-Maria Valls, Anna Pedret, Núria Taltavull, Marta Romeu, Montse Giralt, Manuel Montero, Gloria Bernal, Jenny Faba, Laura Pérez-Merino, Roser Gonzalez, Maria-Carmen Casajuana, Áurea Rodríguez, Luis Arola, Francesc Puiggrós, Ingrid Möller, Carles Chetrit, Daniel Martinez-Puig, Rosa Solà

Abstract

Purpose: To determine the effects of the intake of low-fat yoghurt supplemented with rooster comb extract (RCE) on muscle strength.

Methods and results: 148 subjects, with mild knee pain, participated in a randomized, placebo-controlled, double-blind, and parallel study. Muscle strength, knee effusion, and pain perception were measured. C2C12 myoblasts were used to elucidate the mechanisms of action involved. RCE improved total work and mean power in men, and also peak torque in extension by 10%. RCE reduced synovial effusion by 11.8% and pain perception by 24.6%. Both RCE and HA increased myoblast proliferation by 29%, while RCE reduced myoblast differentiation by 36.2%, suggesting a beneficial role of RCE in muscle regeneration.

Conclusions: Low-fat yoghurt supplemented with RCE improved muscle strength. This effect is partially explained by muscle regeneration enhancement, reduced synovial effusion, and reduced pain perception, which could exert a beneficial clinical impact on men affected by mild knee pain.


Blood cells transcriptomics as source of potential biomarkers of articular health improvement: effects of oral intake of a rooster combs extract rich in hyaluronic acid

Author(s): Juana Sánchez, M. Luisa Bonet, Jaap Keijer, Evert M. van Schothorst, Ingrid Möller, Carles Chetrit, Daniel Martinez-Puig, Andreu Palou

Abstract

The aim of the study was to explore peripheral blood gene expression as a source of biomarkers of joint health improvement related to glycosaminoglycan (GAG) intake in humans. Healthy individuals with joint discomfort were enrolled in a randomized, double-blind, placebo-controlled intervention study in humans. Subjects ate control yoghurt or yoghurt supplemented with a recently authorized novel food in Europe containing hyaluronic acid (65 %) from rooster comb (Mobilee™ as commercial name) for 90 days. Effects on functional quality-of-life parameters related to joint health were assessed. Whole-genome microarray analysis of peripheral blood samples from a subset of 20 subjects (10 placebo and 10 supplemented) collected pre- and post-intervention was performed. Mobilee™ supplementation reduced articular pain intensity and synovial effusion and improved knee muscular strength indicators as compared to placebo. About 157 coding genes were differentially expressed in blood cells between supplemented and placebo groups post-intervention, but not pre-intervention (p < 0.05; fold change ≥1.2). Among them, a reduced gene expression of glucuronidase-beta (GUSB), matrix metallopeptidase 23B (MMP23B), xylosyltransferase II (XYLT2), and heparan sulfate 6-O-sulfotransferase 1 (HS6ST1) was found in the supplemented group. Correlation analysis indicated a direct relationship between blood cell gene expression of MMP23B, involved in the breakdown of the extracellular matrix, and pain intensity, and an inverse relationship between blood cell gene expression of HS6ST1, responsible for 6-O-sulfation of heparan sulfate, and indicators of knee muscular strength. Expression levels of specific genes in blood cells, in particular genes related to GAG metabolism and extracellular matrix dynamics, are potential biomarkers of beneficial effects on articular health.

A low-fat yoghurt supplemented with a rooster comb extract on muscle joint function in adults with mild knee pain: a randomized, double blind, parallel, placebo-controlled, clinical trial of efficacy

Author(s): Rosa Solà, Rosa-Maria Valls, Isabel Martorell, Montserrat Giralt, Anna Pedret, Núria Taltavull,  Marta Romeu,  Àurea Rodríguez, David Moriña, Victor Lopez de Frutos, Manuel Montero, Maria-Carmen Casajuana, Laura Pérez, Jenny Faba, Gloria Bernal, Anna Astilleros, Roser González, Francesc Puiggrós, Lluís Arola, Carlos Chetrite and Daniel Martinez-Puige

Abstract 

Preliminary results suggested that oral-administration of rooster comb extract (RCE) rich in hyaluronic acid (HA) was associated with improved muscle strength. Following these promising results, the objective of the present study was to evaluate the effect of low-fat yoghurt supplemented with RCE rich in HA on muscle function in adults with mild knee pain; a symptom of early osteoarthritis. Participants (n = 40) received low-fat yoghurt (125 mL d(-1)) supplemented with 80 mg d(-1) of RCE and the placebo group (n = 40) consumed the same yoghurt without the RCE, in a randomized, controlled, double-blind, parallel trial over 12 weeks. Using an isokinetic dynamometer (Biodex System 4), RCE consumption, compared to control, increased the affected knee peak torque, total work and mean power at 180° s(-1), at least 11% in men (p < 0.05) with no differences in women. No dietary differences were noted. These results suggest that long-term consumption of low-fat yoghurt supplemented with RCE could be a dietary tool to improve muscle strength in men, associated with possible clinical significance. However, further studies are needed to elucidate reasons for these sex difference responses observed, and may provide further insight into muscle function.

GPX-4™ Clinical Studies

Low Molecular Weight Collagen Peptide (LMWCP) Promotes Hair Growth by Activating the Wnt/GSK-3β/β-Catenin Signaling Pathway

Author(s): Yujin Kim, Jung Ok Lee, Jung Min Lee, Mun-Hoe Lee3, Hyeong-Min Kim, Hee-Chul Chung3, Do-Un Kim, Jin-Hee Lee, and Beom Joon Kim

Abstract 

Low molecular weight collagen peptide (LMWCP) is a collagen hydrolysate derived from fish. We investigated the effects of LMWCP on hair growth using human dermal papilla cells (hDPCs), human hair follicles (hHFs), patch assay, and telogenic C57BL/6 mice, while also examining the underlying mechanisms of its action. LMWCP promoted proliferation and mitochondrial potential, and the secretion of hair growth-related factors, such as EGF, HB-EGF, FGF-4, and FGF-6 in hDPCs. Patch assay showed that LMWCP increased the neogeneration of new HFs in a dose-dependent manner. This result correlated with an increase in the expression of dermal papilla (DP) signature genes such as, ALPL, SHH, FGF7, and BMP-2. LMWCP upregulated phosphorylation of glycogen synthase kinase-3β (GSK-3β) and β-catenin, and nuclear translocation of β-catenin, and it increased the expression of Wnt3a, LEF1, VEGF, ALP, and β-catenin. LMWCP promoted the growth of hHFs and increased the expression of β-catenin and VEGF. Oral administration of LMWCP to mice significantly stimulated hair growth. The expression of Wnt3a, β-catenin, PCNA, Cyclin D1, and VEGF was also elevated in the back skin of the mice. Furthermore, LMWCP increased the expression of cytokeratin and Keratin Type I and II. Collectively, these findings demonstrate that LMWCP has the potential to increase hair growth via activating the Wnt/β-catenin signaling pathway.

Oral Supplementation with Low-molecular-weight Collagen Peptide Improves Hydration, Facial Lifting, Dermal Density, Skin Desquamation and Nails: A Randomized, Double-blind, Placebo-controlled, and Maintenance of Effect Study

Author(s): Sun Hwa Lee, Hye Kyong Park, Hye Ji Lee, Ah Reum Jo, Eun-Ju Lee, Se-Hee Hwang, Hee-Chul Chung, Jin-Hee Lee, Do-Un Kim, Jongsung Lee and Tae Kee Moon.

Abstract 

Background: Oral low-molecular-weight collagen peptide (LMWCP) hydrolyzed enzymatically is a fish-derived type I collagen hydrolysate with more than 15% of its content made up of tripeptides in the form of Gly-X-Y (X and Y are placed arbitrarily, but are often occupied by proline, hydroxyproline, and alanine) including 3% Gly-Pro-Hyp. LMWCP helps with skin hydration, wrinkles and elasticity via previous findings, has been recognized individually by the Ministry of Food and Drug Safety (MFDS notice No. 2013-30) as a functional food ingredient. In this study, to expand the scope of diversity in the efficacy of LMWCP, we evaluated hydration according to depth of the stratum corneum, facial lifting, dermal density, skin thickness, skin desquamation, and roughness of the nail plate surface. Moreover, the measurement timelines were considered including the early time intake and off-intake periods. 

Methods and materials: This study was designed as a double-blind, randomized, placebo-controlled for 14 weeks including oral intake for 12 weeks followed by 2 weeks of the off-intake period. Water content (depths of 0.1 mm, 0.5 mm), facial lifting, dermal density, skin thickness and skin desquamation were assessed at baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks after intake of the oral supplementation and after 2 weeks of off-intake (+2W). The roughness of the fingernail plate was measured at 0W, 8W and 12W. 

Results: The test group saw significant improvements compared to the placebo group. According to each measurement result, the skin moisture (depth of 0.1 mm) and skin desquamation were improved after 2 weeks of ingestion, and the skin moisture (depth of 0.5 mm), facial lifting, dermal density and skin thickness were improved after 4 weeks. For all measurement items, even after 2 weeks of off-intake, the test group showed a statistically significant improvement compared to the placebo group. In the roughness of the fingernail plate, it was found that the roughness was improved in the test group after 12 weeks compared to before ingestion. 

Discussion: These results demonstrated that the effects of LMWCP appear in early-intake and are maintained even after off-intake. This study suggests LMWCP as a safe and effective ingredient for anti-skin aging in the nutricosmetic market targeting both internal and external beauty and health.

Oral Supplementation of Low-Molecular-Weight Collagen Peptides Reduces Skin Wrinkles and Improves Biophysical Properties of Skin: A Randomized, Double-Blinded, Placebo-Controlled Study

Author(s): Jemin Kim, Sang Gyu Lee, Joohee Lee, Sooyeon Choi, Jangmi Suk, Ju Hee Lee, Joo Hwan Yang, Joon Sung Yang, Jihee Kim 

Abstract 

Orally administered collagen peptides could contribute to antiaging by replacing the degraded extracellular matrix proteins caused by photoaging. This study aimed to evaluate the efficacy and safety of low-molecular-weight collagen peptides for treating photoaged and dry skin. In this randomized, placebo-controlled, parallel-group, double-blinded trial, we randomly assigned study participants (n = 100) to either the test product group or placebo group at a 1:1 ratio for 12 weeks. The wrinkle scale score, eye wrinkle volume, roughness parameters, such as the average maximum height of the wrinkle (Rz), arithmetic average within the total measuring length of the wrinkle (Ra), maximum profile valley depth of the wrinkle (Rv), and skin hydration, transepidermal water loss (TEWL), overall elasticity (R2), and ratio of elastic recovery to total deformation (R7) were evaluated at baseline, 6 weeks, and 12 weeks. Safety assessments with serial blood tests were also conducted. Efficacy assessments of data from 84 participants were conducted as the per-protocol analysis. After 12 weeks, the 10-grade crow's feet photo scale score, eye wrinkle volume, skin roughness parameters (Rz, Ra, and Rv), skin elasticity (R2 and R7), skin hydration, and TEWL were significantly improved in the test product group compared to the placebo group. There were no adverse events or abnormalities according to laboratory analysis associated with using the test material during the study period. This study showed that the oral supplementation of low-molecular-weight collagen peptides could improve the wrinkles, elasticity, hydration, and barrier integrity of photoaged facial skin. This clinical study was registered with the Korean Clinical Research Information Service and International Clinical Trials Registry Platform (No: KCT0006500).

Dermial® Clinical Studies Overview 

A Novel Hyaluronic Acid Matrix Ingredient with Regenerative, Anti-Aging and Antioxidant Capacity

Author(s): Patricia Galvez-Martin, Cristina Soto-Fernandez, Jessica Romero-Rueda, Jesus Cabañas, Anna Torrent, Gloria Castells, and Daniel Martinez-Puig 

Abstract 

Hyaluronic acid (HA) and proteoglycans (such as dermatan sulphate (DS) and chondroitin sulphate (CS)) are the main components of the extracellular matrix of the skin, along with collagen and elastin. These components decrease with age, which implies a loss of skin moisture causing wrinkles, sagging and aging. Currently, the external and internal administration of effective ingredients that can reach the epidermis and dermis is the main alternative for combating skin aging. The objective of this work was to extract, characterise and evaluate the potential of an HA matrix ingredient to support anti-aging. The HA matrix was isolated and purified from rooster comb and characterised physicochemically and molecularly. In addition, its regenerative, anti-aging and antioxidant potential and intestinal absorption were evaluated. The results show that the HA matrix is composed of 67% HA, with an average molecular weight of 1.3 MDa; 12% sulphated glycosaminoglycans, including DS and CS; 17% protein, including collagen (10.4%); and water. The in vitro evaluation of the HA matrix's biological activity showed regenerative properties in both fibroblasts and keratinocytes, as well as moisturizing, anti-aging and antioxidant effects. Furthermore, the results suggest that the HA matrix could be absorbed in the intestine, implying a potential oral as well as topical use for skin care, either as an ingredient in a nutraceutical or a cosmetic product.

Oral Supplementation with a New Hyaluronic Acid Matrix Ingredient Improves Skin Brightness, Hydration, Smoothness, and Roughness: Results from a Randomized, Double‑Blinded, Placebo‑Controlled Study

Author(s): Trinidad Montero‑Vilchez, Patricia Gálvez‑Martín, Raquel Sanabria‑de la Torre, Carlos Cuenca‑Barrales, Alejandro Molina‑Leyva, Daniel Martinez‑Puig, Javier Velasco‑Alvarez, Salvador Arias‑Santiago

Abstract

Introduction: The skin aging process is mainly associated with the appearance of fine wrinkles and flaccid, dry, and dull skin. A hyaluronic acid matrix (HAm) ingredient containing HA, sulfated glycosaminoglycans (GAGs), and collagen is proposed to enhance skin health by improving hydration and structural integrity. The objective of this study was to evaluate the impact of oral supplementation with HAm on skin properties.

Methods: A 12-week, randomized, double-blind, placebo-controlled trial was designed, including 60 healthy women aged 35-65 with signs of natural skin aging (NCT05813054). Participants were assigned to receive either HAm (Dermial®; 60 mg daily) or a placebo and were dermatologically assessed after 6 and 12 weeks. Skin properties were determined by the evaluation of stratum corneum hydration (SCH), brightness/glow, wrinkles, dryness, roughness, smoothness, pH, temperature, elasticity, friction, antioxidant capacity, deformability, melanin index, and erythema index. In addition, global satisfaction and adverse reactions were assessed.

Results: Assessments were performed on data from 50 participants as a per-protocol analysis. Skin wrinkles and smoothness (6 weeks), and roughness (12 weeks) significantly improved in the HAm group compared with the placebo group. Participants receiving HAm had significantly increased skin SCH and brightness, and decreased scaliness and temperature at 6 and 12 weeks versus the baseline value. A statistically significant reduction in the erythema index and a balanced pH were also observed in the HAm group. Global satisfaction was significantly higher in HAm as compared to placebo. No serious adverse events associated with the tested products were registered during the study.

Conclusions: Daily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. These results support the role of HAm in promoting skin brightness/glow and hydration, and reducing the visible effects of aging.

Cerebiome® Clinical Studies

Assessment of psychotropic-like properties of a probiotic formulation(Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects

Author(s): Michaël Messaoudi 1, Robert Lalonde, Nicolas Violle, Hervé Javelot, Didier Desor, Amine Nejdi, Jean-François Bisson, Catherine Rougeot, Matthieu Pichelin, Murielle Cazaubiel, Jean-Marc Cazaubiel

In a previous clinical study, a probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) decreased stress-induced gastrointestinal discomfort. Emerging evidence of a role for gut microbiota on central nervous system functions therefore suggests that oral intake of probiotics may have beneficial consequences on mood and psychological distress. The aim of the present study was to investigate the anxiolytic-like activity of PF in rats, and its possible effects on anxiety, depression, stress and coping strategies in healthy human volunteers. In the preclinical study, rats were daily administered PF for 2 weeks and subsequently tested in the conditioned defensive burying test, a screening model for anti-anxiety agents. In the clinical trial, volunteers participated in a double-blind, placebo-controlled, randomised parallel group study with PF administered for 30 d and assessed with the Hopkins Symptom Checklist (HSCL-90), the Hospital Anxiety and Depression Scale (HADS), the Perceived Stress Scale, the Coping Checklist (CCL) and 24 h urinary free cortisol (UFC). Daily subchronic administration of PF significantly reduced anxiety-like behaviour in rats (P < 0·05) and alleviated psychological distress in volunteers, as measured particularly by the HSCL-90 scale (global severity index, P < 0·05; somatisation, P < 0·05; depression, P < 0·05; and anger-hostility, P < 0·05), the HADS (HADS global score, P < 0·05; and HADS-anxiety, P < 0·06), and by the CCL (problem solving, P < 0·05) and the UFC level (P < 0·05). L. helveticus R0052 and B. longum R0175 taken in combination display anxiolytic-like activity in rats and beneficial psychological effects in healthy human volunteers.

Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers

Author(s): Michaël Messaoudi, Nicolas Violle,Jean-François Bisson, Didier Desor, Hervé Javelot and Catherine Rougeot

Abstract 

In a recent clinical study, we demonstrated in the general population that Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) taken in combination for 30 days decreased the global scores of hospital anxiety and depression scale (HADs), and the global severity index of the Hopkins symptoms checklist (HSCL-90), due to the decrease of the sub-scores of somatization, depression and anger-hostility spheres. Therefore, oral intake of PF showed beneficial effects on anxiety and depression related behaviors in human volunteers. From there, it is interesting to focus on the role of this probiotic formulation in the subjects with the lowest urinary free cortisol levels at baseline.

Probiotic food supplement reduces stress-induced gastrointestinal symptoms in volunteers: a double-blind, placebo-controlled, randomized trial

Author(s): Laurent Diopa, Sonia Guilloub, Henri Durandc

Abstract 

Stress plays an important role in the development of symptoms contributing to disease. Stress induces various disorders with gastrointestinal, physical, and psychological symptoms. Probiotics can help regulate or modulate gastrointestinal functions. The aim of the present study was to investigate the effects of a probiotic preparation (Probio-Stick) on stress-induced symptoms in volunteers. A double-blind, placebo-controlled, randomized study was conducted on volunteers with symptoms of stress. Subjects received a probiotic (Probio-Stick; Lallemand SAS, Saint-Simon, France) containing Lactobacillus acidophilus Rosell-52 and Bifidobacterium longum Rosell-175 (3 x 10(9) colony-forming units per sachet stick) or a sensorially identical placebo without probiotics during a 3-week period. The consumption of probiotics significantly reduced 2 stress-induced gastrointestinal symptoms (abdominal pain and nausea/vomiting) for intention-to-treat or per-protocol populations. In contrast, the probiotics did not significantly modify the other physical and psychological symptoms and sleep problems induced by stressful life events for intention-to-treat or per-protocol populations. The results indicate that Probio-Stick can provide a beneficial effect on the gastrointestinal symptoms experienced by individuals affected by chronic stress.

A Subjective Evaluation of the Effects of a Probiotic Formulation on Skin Quality in Young Adult Females: Open-Label Proof-of-Concept Study

Author(s): Ola Kassem, Annie Tremblay, Mark S.W. Ghaly, Marie-Laure Oula

Abstract

This pilot, proof-of-concept, study was designed to assess the effect of a blend of Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 on parameters of skin quality. Capsules containing L. helveticus Rosell®-52 and B. longum Rosell®-175 were given to 35 healthy women (3 billion CFU/d for 56 days), and assessments of skin quality were performed at baseline, as well as on days 28 and 56. Importantly, the formulation significantly reduced the appearance of fine lines and improved skin firmness, elasticity, and hydration. In addition, study participants experienced improvements in sleep quality and felt less stressed (PSS-10 subjective stress questionnaire). Taken together, these results provide the rationale to conduct a larger, placebo-controlled trial and to assess the effects of the oral probiotic intake in healthy women with more visible signs of skin aging.

Evaluating the Impact of Probiotic Therapy on the Endocannabinoid System, Pain, Sleep and Fatigue: A Randomized, Double-Blind, Placebo-Controlled Trial in Dancers

Author(s): Laurent Diopa, Sonia Guillou, Henri Durand

Abstract 

Emerging research links the endocannabinoid system to gut microbiota, influencing nociception, mood, and immunity, yet the molecular interactions remain unclear. This study focused on the effects of probiotics on ECS markers—cannabinoid receptor type 2 (CB2) and fatty acid amide hydrolase (FAAH)—in dancers, a group selected due to their high exposure to physical and psychological stress. In a double-blind, placebo-controlled trial (ClinicalTrials.gov NCT05567653), 15 dancers were assigned to receive either a 12-week regimen of Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-17 or a placebo (PLA: n = 10, PRO: n = 5). There were no significant changes in CB2 (probiotic: 0.55 to 0.29 ng/mL; placebo: 0.86 to 0.72 ng/mL) or FAAH levels (probiotic: 5.93 to 6.02 ng/mL; placebo: 6.46 to 6.94 ng/mL; p > 0.05). A trend toward improved sleep quality was observed in the probiotic group, while the placebo group showed a decline (PRO: from 1.4 to 1.0; PLA: from 0.8 to 1.2; p = 0.07841). No other differences were noted in assessed outcomes (pain and fatigue). Probiotic supplementation showed no significant impact on CB2 or FAAH levels, pain, or fatigue but suggested potential benefits for sleep quality, suggesting an area for further research.

Collavant® n2, Dermial® is Mobilee® a registered trademark licensed by BIOIBERICA, S.A.U. GPX-4™ is a licensed trademark of Newtree Co. LTD. Cerebiome is a registered trademark of Danstar Ferment AG. 

To respect contractual obligations and intellectual property rights, this summary highlights publicly available abstracts that contain a summary of the clinical findings. It does not contain the full text of the original studies.